DC、CIK、CD3AK Transfusion Therapy On Immune Function In Patients With Advanced Cancer

Objective:By comparing the change of CD3+T cells, CD4+T cells, CD8+T cells and CD4+ T/CD8+ T cell ratio before and after DC,CIK,CD3AK cell reinfusion in the late cancer patients, investigate the impact of immune function of cancer patients with DC、 CD3 AK transfusion therapy.Methods:Collecting 111 cases of cancer patients with DC、CIK、CD3AK transfusion therapy in April 2014-December our department. The percentage of CD3+T cells, CD4+T cells, CD8+T cells were detected by flow cytometry and calculate the ratio of CD4+ T/CD8+ T cells. Results: ①The percentage of CD3+ T cells, CD4+T cells and the ratio of CD4+ T/CD8+ T cells of all patients were improved after DC、CIK、CD3AK transfusion therapy,but the percentage of CD8+ T cells decreased, The difference was statistically significant; ② Every kind of disease have the same result;③ Comparing Multi-course group with Single course group, chemoradiotherapy group with no chemoradiotherapy group T-lymphocyte subsets have the similar results,but multiple courses of T cell subsets in groups larger than a single course and Chemoradiotherapy group is greater than no combined group(P<0.05).Conclusion: Multi-cell transfusion therapy can significantly improve the immune function in cancer patients, and the result of Multi-course group has obvious advantages comparing with Single course group, and combining with chemotherapy can increase its efficacy.